Immunocore reaches 540-patient enrollment target in Phase 3 TEBE-AM trial of Kimmtrak in advanced melanoma

• Immunocore reached target enrollment of 540 patients in the Phase 3 TEBE-AM trial of KIMMTRAK in previously treated advanced melanoma.
• The study evaluates tebentafusp alone or with pembrolizumab versus investigator’s choice in HLA-A 02:01-positive patients whose disease progressed post-PD-1 therapy.
• Results have not been presented; topline overall survival data are expected as early as end-2026.
• The milestone keeps the program on track for a potential new option in a setting with limited therapies, supporting a larger commercial opportunity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein.